{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CONMED Corp. Stock Plummets to New 52-Week Low of $34.54
CONMED Corp. has reached a new 52-week low, reflecting a difficult year marked by a significant decline in stock price and net profit. The company, with a market capitalization of USD 1,231 million and a P/E ratio of 18.00, has struggled with growth and operating profit challenges.
CONMED Corp. Experiences Revision in Stock Evaluation Amid Market Challenges
CONMED Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has experienced a challenging year with a significant decline in stock performance compared to the S&P 500. Current market indicators show mixed signals, suggesting potential volatility as the company navigates its competitive landscape.
CONMED Corp. Experiences Valuation Adjustment Amidst Competitive Market Dynamics
CONMED Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has experienced a valuation adjustment, with its stock price declining recently. Over the past year, the company has faced challenges, reflected in its negative stock return. Key financial metrics indicate a mixed valuation landscape compared to peers.
CONMED Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape
CONMED Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation metrics, including a P/E ratio of 18 and a high dividend yield of 155.87%. The company faces competition from peers with varying valuations, emphasizing the significance of performance indicators in assessing market position.
CONMED Corp. Stock Plummets to New 52-Week Low of $42.50
CONMED Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,777 million, faces challenges in growth and profitability, evidenced by a notable decrease in net profit and ongoing scrutiny from institutional investors.
CONMED Corp. Hits New 52-Week Low at USD 45.11 Amid Decline
CONMED Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year. The company, with a market capitalization of USD 1,777 million, faces challenges in growth despite high institutional holdings and a notable dividend yield. Its financial metrics indicate a fair valuation relative to assets.
Is CONMED Corp. technically bullish or bearish?
As of August 1, 2025, CONMED Corp. is in a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, showing a year-to-date return of -24.87% versus the S&P's 12.22%.
Is CONMED Corp. overvalued or undervalued?
As of June 30, 2025, CONMED Corp. is considered undervalued with a P/E ratio of 21 and an attractive valuation grade, but it has underperformed the S&P 500 with a year-to-date return of -24.87%, raising concerns about its growth prospects.
Is CONMED Corp. technically bullish or bearish?
As of June 27, 2025, CONMED Corp. is in a bearish trend with moderate strength, driven by bearish daily moving averages and monthly MACD, despite some mildly bullish signals from weekly indicators, and has significantly underperformed the S&P 500.
Is CONMED Corp. technically bullish or bearish?
As of June 13, 2025, CONMED Corp. is in a bearish trend with moderate strength, driven by bearish signals from moving averages and Bollinger Bands, despite some mixed indicators like the MACD and KST showing mild bullishness on the weekly timeframe.
Is CONMED Corp. overvalued or undervalued?
As of April 30, 2025, CONMED Corp. is fairly valued with a P/E ratio of 21 and an EV to EBITDA of 13.82, but has underperformed the S&P 500 with a year-to-date return of -24.50%, indicating potential challenges in meeting growth expectations despite not being overvalued.
What does CONMED Corp. do?
CONMED Corporation is a medical technology company that develops and sells surgical devices for minimally invasive procedures. As of March 2025, it reported net sales of $319 million and a market cap of $1.72 billion.
How big is CONMED Corp.?
As of Jun 18, CONMED Corp. has a market capitalization of $1.72 billion, with net sales of $1.31 billion and a net profit of $118.75 million over the latest four quarters. The balance sheet shows shareholder's funds of $962.68 million and total assets of $2.31 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
